Drugs / JNJ-61803534
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03139500 | May 2017 → Apr 2018 | — | Janssen Research & Development, LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-61803534 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03139500 ↗ |
| Route | Oral | “Participants will receive JNJ-61803534 tablets orally.” NCT03139500 ↗ |